Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 17/20 | 0.55 |
| ▸ | CA1 | P00915 | 17/20 | 0.55 |
| ▸ | CA2 | P00918 | 17/20 | 0.55 |
| ▸ | CA7 | P43166 | 17/20 | 0.55 |
| ▸ | CA4 | P22748 | 14/20 | 0.55 |
| ▸ | CA5A | P35218 | 14/20 | 0.55 |
| ▸ | CA5B | Q9Y2D0 | 14/20 | 0.55 |
| ▸ | MAOB | P27338 | 12/20 | 0.55 |
| ▸ | CA9 | Q16790 | 4/20 | 0.52 |
| ▸ | MAOA | P21397 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14149692 | 0.86 | CA12 (0.70) | CA12CA1CA2CA7CA4 | |
| SCHEMBL15703716 | 0.85 | MAOB (0.46) | CA12CA1CA2CA7CA4 | |
| SCHEMBL15701608 | 0.83 | RXRA (0.46) | CA12CA1CA2CA7CA4 | |
| SCHEMBL14149585 | 0.82 | CA12 (0.50) | CA12CA1CA2CA7CA4 | |
| SCHEMBL14058897 | 0.76 | LMNA (0.51) | CA12CA1CA2CA7CA4 | |
| SCHEMBL30069959 | 0.76 | ALOX5 (0.56) | CA12CA1CA2CA7CA4 | |
| SCHEMBL3101086 | 0.75 | LMNA (0.61) | CA12CA1CA2CA4CA9 | |
| SCHEMBL14061028 | 0.74 | NCF1 (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL14061460 | 0.74 | MEN1 (0.50) | CA12CA1CA2CA7CA4 | |
| SCHEMBL14061023 | 0.73 | LMNA (0.60) | CA12CA1CA2CA7CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346795-B2 | Substituted sulfonamides useful as antiapoptotic Bcl inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-24 | — | — | US | disclosed |
| US-9346795-B2 | Substituted sulfonamides useful as antiapoptotic Bcl inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-24 | — | — | US | disclosed |
| US-9346795-B2 | Substituted sulfonamides useful as antiapoptotic Bcl inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-24 | — | — | US | disclosed |
| CN-103732589-B | Can be used as the sulphonamide of the replacement of anti-apoptotic BCL inhibitor | BRISTOL-MYERS SQUIBB CO. (US) | 2016-03-30 | — | — | CN | disclosed |
| EP-2714681-B1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-06-24 | — | — | EP | disclosed |
| US-20140135318-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140135318-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140135318-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-15 | — | — | US | disclosed |
| WO-2012162365-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135318-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BCL2, BAX, BCL2A1 | CA12 2654/4885CA1 2483/4885CA2 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.